0XI8 Stock Chart & Stats
€125.06
€0.00(0.00%)
At close: 4:00 PM EDT
€125.06
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€125.06 - €125.06
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€18.86B
Enterprise Value€22.19K
Total Cash (Recent Filing)€482.30M
Total Debt (Recent Filing)€2.04B
Price to Earnings (P/E)27.4
BetaN/A
Next Earnings
Nov 11, 2026EPS Estimate
2.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.20
Shares Outstanding97,500,110
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.03
Price to Book (P/B)3.02
Price to Sales (P/S)3.66
P/FCF Ratio22.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€233.65Price Target Upside86.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)9.58
Revenue Forecast (FY)€5.45B
Bulls Say, Bears Say
Bulls Say
Recurring Installed-Base ModelThe combination of capital equipment, replenished consumables and service contracts creates multiple revenue streams across each installed customer base. This supports recurring demand, strengthens customer relationships in regulated settings, and can make revenue more durable than equipment sales alone.
Improving ProfitabilityImproving net profitability alongside steady gross margins indicates that STERIS is converting growth into earnings rather than relying only on volume expansion. Healthy operating profitability can support reinvestment, strengthen resilience, and provide a durable base for future earnings.
Conservative Balance SheetVery low leverage reduces financial risk and preserves flexibility for investment, customer-support infrastructure and other strategic priorities. A stronger balance sheet also gives STERIS greater capacity to manage operating variability without excessive interest costs or refinancing dependence.
Bears Say
Declining Free Cash Flow MomentumAlthough cash generation remains positive, declining free cash flow and conversion below net income indicate that earnings are not translating into expanding discretionary cash at present. If sustained, this could constrain reinvestment, shareholder returns, or flexibility around capital spending.
Restructuring Costs And Higher CapexThe manufacturing and distribution consolidation may improve efficiency over time, but the planned charges and higher capital spending create a multi-year execution burden. These commitments can depress near-term cash generation and increase the importance of realizing the targeted operating benefits.
Moderating Growth And Equipment PressureRevenue growth remains positive, but the latest pace is more moderate than some prior periods and capital equipment demand is facing pressure in certain segments. A slower mix of equipment activity could reduce near-term growth leverage and make results more dependent on recurring sales.
Steris News
0XI8 FAQ
What was Steris plc’s price range in the past 12 months?
Steris plc lowest share price was €125.06 and its highest was €125.06 in the past 12 months.
What is Steris plc’s market cap?
Steris plc’s market cap is €18.86B.
When is Steris plc’s upcoming earnings report date?
Steris plc’s upcoming earnings report date is Nov 11, 2026 which is in 65 days.
How were Steris plc’s earnings last quarter?
Steris plc released its earnings results on Aug 05, 2026. The company reported €2.215 earnings per share for the quarter, beating the consensus estimate of €2.134 by €0.081.
Is Steris plc overvalued?
According to Wall Street analysts Steris plc’s price is currently Undervalued.
Does Steris plc pay dividends?
Steris plc does not currently pay dividends.
What is Steris plc’s EPS estimate?
Steris plc’s EPS estimate is 2.29.
How many shares outstanding does Steris plc have?
Steris plc has 97,500,110 shares outstanding.
What happened to Steris plc’s price movement after its last earnings report?
Steris plc reported an EPS of €2.215 in its last earnings report, beating expectations of €2.134. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Steris plc?
Currently, no hedge funds are holding shares in GB:0XI8
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Steris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€233.65 (86.83% Upside)
€233.65 (86.83% Upside)
Blogger Sentiment
Bullish
GB:0XI8 Sentiment 63%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth €2.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.70%
12-Months-Change
Fundamentals
Return on Equity
1.15%
Trailing 12-Months
Asset Growth
3.18%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Steris plc
STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, surgical tables, lights, and connectivity solutions. It also provides services such as equipment maintenance, instrument repair, and contract sterilization for medical device and pharmaceutical manufacturers.
0XI8 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive financial and operational picture: STERIS delivered a record fiscal 2026 with double-digit adjusted EPS growth, exceptional free cash flow (~$983M), stronger leverage (gross debt/EBITDA ~1.2x), and multiple segment milestones (Healthcare, AST, Life Sciences). Management provided constructive FY2027 guidance (7–8% revenue growth, EPS up ~9–11%, modest margin expansion) while continuing shareholder returns (dividend increase, $1B buyback authorization) and strategic investments (manufacturing consolidation, tuck-in M&A, AI for service). Offsetting these positives are tangible near-term headwinds: tariff costs (~$60–65M annual spend with no refunds assumed), higher effective tax rates due to withholding and geographic mix, Q4 margin compression, AST service softness and inventory-led demand variability, and a forecasted reduction in free cash flow for FY2027. Overall, the highlights — record growth, strong cash generation, prudent capital allocation, and constructive guidance — outweigh the lowlights, which are manageable but notable operational and tax/tariff risks.View all GB:0XI8 earnings summaries0XI8 Revenue Breakdown
73.00% U.S.
25.39% Other locations
1.61% Ireland
0XI8 Stock 12 Month Forecast
Average Price Target
€233.65
▲(86.83% Upside)
Technical Analysis
Anika Therapeutics
―
Apyx Medical
―
Mesa Laboratories
―
QuidelOrtho
―
Trinity Biotech
―